Johsuke Hara

Dr. Johsuke Hara

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KTKatsuyoshi Tomomatsu
Katsuyoshi Tomomatsu
HYHirotaka Yasuba
Hirotaka Yasuba
TITakashi Ishiguro
Takashi Ishiguro
SIShiro Imokawa
Shiro Imokawa
JHJohsuke Hara
Johsuke Hara
KAKoichiro Asano
Koichiro Asano
Despite standard treatment with systemic corticosteroids and/or antifungal triazoles, a substantial proportion of patients with allergic bronchopulmonary aspergillosis (ABPA) experience frequent relapses and require long-term treatment despite unfavorable adverse effects. We investigated the efficacy and safety of anti-interleukin (IL)-5/IL-5 receptor α chain (Rα) monoclonal antibodies (mAbs) in patients with ABPA complicated by asthma. ABPA cases treated with anti-IL-5/IL-5Rα mAbs were collected from 132 medical institutes in 2018 and published case reports in Japan. Clinical outcomes, laboratory and physiological data, and radiographic findings during 32 weeks before and after treatment were retrospectively evaluated. We analyzed 29 cases of ABPA: 20 treated with mepolizumab and nine with benralizumab. Treatment with anti-IL-5/IL-5Rα mAbs reduced the frequency of exacerbations (p = 0.03), decreased the dose of oral corticosteroids (p < 0.01), and improved pulmonary function (p = 0.01). Mucus plugs in the bronchi shrank or diminished in 18 patients (82%). Despite the clinical/radiographical improvement, serum levels of total IgE, the key biomarker for the pharmacological response in ABPA, were unchanged. Anti-IL-5/IL-5Rα mAbs that directly target eosinophils are promising candidates for the treatment of patients with ABPA, especially those with mucus plugs in the bronchi.

8 June 2024 in Chest
Verified
Journal Article
Closed access
SYShota Yamamoto
Shota Yamamoto
NHNobuyuki Horita
Nobuyuki Horita
JHJohsuke Hara
Johsuke Hara
MSMao Sasamoto
Mao Sasamoto
YKYoshihiro Kanemitsu
Yoshihiro Kanemitsu
HMHiroshi Mukae
Hiroshi Mukae

1 October 2016 in Allergology International
Verified
Journal Article
Open access
SWSatoshi Watanabe
Satoshi Watanabe
HKHideharu Kimura
Hideharu Kimura
HTHazuki Takato
Hazuki Takato
YWYuko Waseda
Yuko Waseda
JHJohsuke Hara
Johsuke Hara
KKKazuo Kasahara
Kazuo Kasahara

TNThao Nguyen
Thao Nguyen
THTomomi Higashi
Tomomi Higashi
YKYasuhiro Kambayashi
Yasuhiro Kambayashi
EAEnoch Olando Anyenda
Enoch Olando Anyenda
YMYoshimasa Michigami
Yoshimasa Michigami
HNHiroyuki Nakamura
Hiroyuki Nakamura
The association between heavy metals exposure and respiratory diseases or allergic sensitization showing high serum immunoglobulin E (IgE) has been suggested. However, previous findings have been inconsistent and the mechanisms responsible remain unclear. We evaluated heavy metal exposure and its association with coughing, itchy eyes in chronic cough patients with different IgE levels. Ninety outpatients in Kanazawa University Hospital were recruited between January–June 2011. Subjects whose total IgE measured by radioimmunosorbent test were asked to record their daily symptoms. We collected daily total suspended particles (TSP) from which concentrations of calcium (Ca), cadmium (Cd), chromium (Cr), iron (Fe), manganese (Mn), nickel (Ni), and lead (Pb) were determined then divided into high and low level groups. Generalized estimating equations were applied to compute the relationship between concentrations of these metals and symptoms. All metals at high levels were significantly associated with itchy eyes compared with low levels, with exception of Ca, the six others were significant in patients with IgE < 250 IU/mL. Cd, Fe, Mn had association with coughing (odds ratio-OR (95% confidence interval-CI): 1.13 (1.03, 1.24), 1.22 (1.05, 1.42), and 1.13 (1.01, 1.27), respectively), this relationship remained significant for Cd (OR (95% CI): 1.14 (1.03, 1.27)) and Mn (OR (95% CI): 1.15 (1.00, 1.31)) in patients with lower IgE. Our findings demonstrate the relationship between aerial heavy metals and itchy eyes, coughing in chronic cough patients, suggesting these symptoms may be due to a non-IgE mediated mechanism.

EAEnoch Olando Anyenda
Enoch Olando Anyenda
THTomomi Higashi
Tomomi Higashi
YKYasuhiro Kambayashi
Yasuhiro Kambayashi
TNThao Nguyen
Thao Nguyen
YMYoshimasa Michigami
Yoshimasa Michigami
HNHiroyuki Nakamura
Hiroyuki Nakamura
Information on potential cough triggers including environmental irritants is vital for successful management of chronic cough in patients. We investigated the relationship between ambient levels of particulate polycyclic aromatic hydrocarbons (PAH), nitrogen dioxide (NO2) and sulphur dioxide (SO2) exposures with cough prevalence. Eighty-three adult patients, who had been physician diagnosed with at least asthma, cough variant asthma and/or atopic cough, were divided into asthma and non-asthma groups. They recorded daily cough symptoms during 4 January–30 June 2011 study period while daily samples of total suspended particles were simultaneously collected by use of glass fiber filters and the particulate PAH content determined by high performance liquid chromatography coupled with a fluorescence detector. Ambient concentrations of NO2 and SO2 were obtained from a local monitoring site. Logistic regression models using generalized estimating equations were used to determine population-averaged estimates of association between cough prevalence and ambient pollutant exposures for the two groups. Fully adjusted odds ratios from single pollutant models were 1.083 (95% confidence interval (CI): 1.029, 1.140) and 1.097 (95% CI: 1.016, 1.185) per 0.57 ng/m3 for lag2 PAH exposure, while only for asthma group had significant associations with NO2 and SO2 exposures for both lag2 and lag02. Similar associations were observed in multipollutant models. This finding suggests that ambient PAH, NO2, and SO2 exposure even at low levels is related to cough prevalence in adult chronic cough patients and may be considered as aggravating factor during clinical management of the condition.